Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 2016, 31: 342-345. PMID: 27813521, PMCID: PMC5306454, DOI: 10.1038/eye.2016.233.Peer-Reviewed Original ResearchAflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 2016, 30: 1531-1541. PMID: 27564719, PMCID: PMC5177746, DOI: 10.1038/eye.2016.174.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaMacular edemaLarge phase 3 trialsBetter baseline VAEfficacy of afliberceptRole of afliberceptSecondary therapeutic optionsPhase 3 trialProtocol TBaseline VABimonthly regimenNata protocolAnatomic outcomesTherapeutic optionsPoor visionTreatment strategiesPrimary drugAfliberceptDifferent dosesDoseRanibizumabRegimenEdemaPatientsRecent data